Plasma neurofilament light chain as prognostic marker of cognitive decline in neurodegenerative diseases, a clinical setting study DOI Creative Commons

Karl Götze,

Agathe Vrillon, Julien Dumurgier

et al.

Alzheimer s Research & Therapy, Journal Year: 2024, Volume and Issue: 16(1)

Published: Oct. 19, 2024

Analysis of selected research cohorts has highlighted an association between plasma neurofilament light (NfL) protein and cross-sectional cognitive impairment as well longitudinal decline. However, the findings have yielded inconsistent results regarding its possible application in clinical practice. Despite potential prognostic significance, role NfL daily practice with unselected patients suffering from remains largely unexplored. This retrospective, monocentric study enrolled 320 Alzheimer's disease ([AD], n = 158), dementia Lewy body ([DLB], 30), frontotemporal ([FTD], 32), non-neurodegenerative diseases ([NND], 59) or subjective decline ([SCD], 41). Plasma levels were measured at baseline on Simoa platform. AD, DLB, FTD also analyzed altogether a 'degenerative conditions' subgroup, whereas SCD NND grouped 'non-degenerative subgroup. We assessed relationship performance, including global cognition six specific domains. A subset 239 had follow-up mini-mental state examinations (MMSE) up to 60 months. Models adjusted age, education level, glomerular filtration rate mass index. In patients, negatively associated (β=-1.28 (-1.81 ; -0.75) P < 0.001), memory (β=-1.48 (-2.38 -0.59), language (β=-1.72(-2.49 -0.95) praxis (β=-2.02 (-2.91 -1.13) 0.001) executive functions (β=-0.81, 0.001). Across diagnosis, all but specifically AD (respectively β=-0.71(-1.21 -0.211), 0.005 β=-1.29 (-2.17 -0.42), 0.004), attention LBD (β=-0.81(-1.16 -0.002), 0.03). Linear mixed-effects models showed that predicted MMSE population (βPlasmaNfLxTime=-0.15 (-0.26 -0.04), 0.006), neurodegenerative condition subgroup (βPlasmaNfLxTime=-0.21 (-0.37 − 0.06), 0.007), not our cohort, was faster dementia, which corroborates data obtained cohorts. Yet, predictive accelerated individuals without neurodegeneration, suggesting use neurodegeneration-specific biomarker.

Language: Английский

Plasma and CSF neurofilament light chain distinguish neurodegenerative from primary psychiatric conditions in a clinical setting DOI Creative Commons
Dhamidhu Eratne, Matthew Kang, Courtney Lewis

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 12, 2024

ABSTRACT INTRODUCTION Many patients with neurodegenerative disorders (ND) face diagnostic delay and misdiagnosis. We investigated blood cerebrospinal fluid (CSF) neurofilament light chain (NfL) to distinguish ND from primary psychiatric (ND), a common challenge in clinical settings. METHODS Plasma CSF NfL levels were measured compared between groups, adjusting for age, sex, weight. RESULTS 337 participants included: 136 ND, 77 PPD, 124 Controls. was 2.5 fold elevated PPD had strong performance (area under the curve, AUC 0.86, 81%/85% specificity/sensitivity) that comparable (2 elevated, 0.89, 95%/71% specificity/sensitivity). Diagnostic especially younger people (40-<60years). Additional findings cut-offs optimised sensitivity specificity, issues important future translation CONCLUSIONS This study adds evidence simple blood-based biomarker assist as screening test neurodegeneration distinction

Language: Английский

Citations

0
A multifactorial lens on risk factors promoting the progression of Alzheimer’s disease DOI

Jenna Parker,

Jose M. Moris, Lily C. Goodman

et al.

Brain Research, Journal Year: 2024, Volume and Issue: 1846, P. 149262 - 149262

Published: Oct. 5, 2024

Language: Английский

Citations

0
Plasma neurofilament light chain as prognostic marker of cognitive decline in neurodegenerative diseases, a clinical setting study DOI Creative Commons

Karl Götze,

Agathe Vrillon, Julien Dumurgier

et al.

Alzheimer s Research & Therapy, Journal Year: 2024, Volume and Issue: 16(1)

Published: Oct. 19, 2024

Analysis of selected research cohorts has highlighted an association between plasma neurofilament light (NfL) protein and cross-sectional cognitive impairment as well longitudinal decline. However, the findings have yielded inconsistent results regarding its possible application in clinical practice. Despite potential prognostic significance, role NfL daily practice with unselected patients suffering from remains largely unexplored. This retrospective, monocentric study enrolled 320 Alzheimer's disease ([AD], n = 158), dementia Lewy body ([DLB], 30), frontotemporal ([FTD], 32), non-neurodegenerative diseases ([NND], 59) or subjective decline ([SCD], 41). Plasma levels were measured at baseline on Simoa platform. AD, DLB, FTD also analyzed altogether a 'degenerative conditions' subgroup, whereas SCD NND grouped 'non-degenerative subgroup. We assessed relationship performance, including global cognition six specific domains. A subset 239 had follow-up mini-mental state examinations (MMSE) up to 60 months. Models adjusted age, education level, glomerular filtration rate mass index. In patients, negatively associated (β=-1.28 (-1.81 ; -0.75) P < 0.001), memory (β=-1.48 (-2.38 -0.59), language (β=-1.72(-2.49 -0.95) praxis (β=-2.02 (-2.91 -1.13) 0.001) executive functions (β=-0.81, 0.001). Across diagnosis, all but specifically AD (respectively β=-0.71(-1.21 -0.211), 0.005 β=-1.29 (-2.17 -0.42), 0.004), attention LBD (β=-0.81(-1.16 -0.002), 0.03). Linear mixed-effects models showed that predicted MMSE population (βPlasmaNfLxTime=-0.15 (-0.26 -0.04), 0.006), neurodegenerative condition subgroup (βPlasmaNfLxTime=-0.21 (-0.37 − 0.06), 0.007), not our cohort, was faster dementia, which corroborates data obtained cohorts. Yet, predictive accelerated individuals without neurodegeneration, suggesting use neurodegeneration-specific biomarker.

Language: Английский

Citations

0